首页> 美国卫生研究院文献>Respiratory Research >Infection-mediated asthma: etiology mechanisms and treatment options with focus on Chlamydia pneumoniae and macrolides
【2h】

Infection-mediated asthma: etiology mechanisms and treatment options with focus on Chlamydia pneumoniae and macrolides

机译:感染介导的哮喘:病因机制和治疗选择重点是肺炎衣原体和大环内酯类

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Asthma is a chronic respiratory disease characterized by reversible airway obstruction and airway hyperresponsiveness to non-specific bronchoconstriction agonists as the primary underlying pathophysiology. The worldwide incidence of asthma has increased dramatically in the last 40 years. According to World Health Organization (WHO) estimates, over 300 million children and adults worldwide currently suffer from this incurable disease and 255,000 die from the disease each year. It is now well accepted that asthma is a heterogeneous syndrome and many clinical subtypes have been described. Viral infections such as respiratory syncytial virus (RSV) and human rhinovirus (hRV) have been implicated in asthma exacerbation in children because of their ability to cause severe airway inflammation and wheezing. Infections with atypical bacteria also appear to play a role in the induction and exacerbation of asthma in both children and adults. Recent studies confirm the existence of an infectious asthma etiology mediated by Chlamydia pneumoniae (CP) and possibly by other viral, bacterial and fungal microbes. It is also likely that early-life infections with microbes such as CP could lead to alterations in the lung microbiome that significantly affect asthma risk and treatment outcomes. These infectious microbes may exacerbate the symptoms of established chronic asthma and may even contribute to the initial development of the clinical onset of the disease. It is now becoming more widely accepted that patterns of airway inflammation differ based on the trigger responsible for asthma initiation and exacerbation. Therefore, a better understanding of asthma subtypes is now being explored more aggressively, not only to decipher pathophysiologic mechanisms but also to select treatment and guide prognoses. This review will explore infection-mediated asthma with special emphasis on the protean manifestations of CP lung infection, clinical characteristics of infection-mediated asthma, mechanisms involved and antibiotic treatment outcomes.
机译:哮喘是一种慢性呼吸系统疾病,其特征在于可逆性气道阻塞和对非特异性支气管收缩激动剂的气道高反应性,这是主要的潜在病理生理学。在过去的40年中,全球哮喘的发病率急剧上升。根据世界卫生组织(WHO)的估计,目前全球每年有3亿儿童和成人患有这种无法治愈的疾病,每年有255,000例儿童死于该疾病。现在,人们普遍认为哮喘是异质综合症,并且已经描述了许多临床亚型。儿童呼吸道合胞病毒(RSV)和人鼻病毒(hRV)等病毒感染由于其引起严重的气道炎症和喘鸣的能力而与哮喘发作有关。在儿童和成人中,非典型细菌的感染也似乎在哮喘的诱发和恶化中起作用。最近的研究证实了由肺炎衣原体(CP)以及其他病毒,细菌和真菌微生物介导的传染性哮喘病因。早期感染如CP的微生物也可能导致肺微生物组发生改变,从而显着影响哮喘风险和治疗效果。这些传染性微生物可能会加剧已建立的慢性哮喘的症状,甚至可能有助于疾病临床发作的初期发展。现在,气道炎症的模式因引起哮喘发作和加重的触发因素而有所不同,这一点已被越来越广泛的接受。因此,现在正在更积极地探索对哮喘亚型的更好理解,不仅是为了了解其病理生理机制,而且还可以选择治疗方法和指导预后。这篇综述将探讨感染介导的哮喘,特别是CP肺部感染的蛋白质表现,感染介导的哮喘的临床特征,涉及的机制和抗生素治疗的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号